PeptidePlaza
The Free Peptide Reference

Insulin Zinc, Prompt

From PeptidePlaza, the free peptide reference · Entry #1220 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Insulin Zinc, Prompt is a metabolic research peptide. Insulin Zinc, Prompt is an insulin receptor agonist currently in Phase 2 clinical trials.

Insulin Zinc, Prompt is a compound classified as an insulin receptor agonist. It functions by activating the insulin receptor, mimicking the action of natural insulin. Research involving this compound has appeared in studies related to conditions such as Maple Syrup Urine Disease, Diabetic Ketoacidosis, and Zinc Deficiency. It is currently undergoing Phase 2 clinical trials.

1 Mechanism of action

Insulin receptor agonist (agonist)

Primary targets: Insulin receptor

2 Chemical and physical properties

Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsInsulin receptor

3 Research studies (7)

  1. Maple Syrup Urine Disease
    (1993) · Review
  2. Diabetic Ketoacidosis Complicating Gestational Diabetes Mellitus
    AACE clinical case reports (2022) · Case Series
  3. Zinc Deficiency Presenting With Diverse Symptoms in a Young Patient: A Case Report
    Cureus (2024) · Case Series
  4. An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists
    Cureus (2022) · Case Series
  5. Diabetes Mellitus Type 1 Presenting in the Setting of Diabetic Ketoacidosis and Acute SARS-CoV-2 Infection in Pregnancy
    AACE clinical case reports (2023) · Case Series
  6. Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform
    Mechanisms of ageing and development (2003)
  7. Kinetic and quantitative relationships between insulin release and 65Zn efflux from perifused islets
    Endocrinology (1985)

4 Safety and risk profile

4.1 Regulatory status

Insulin Zinc, Prompt is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

5 Frequently asked questions

What is Insulin Zinc, Prompt?
Insulin Zinc, Prompt is a compound that acts as an insulin receptor agonist. It is currently in Phase 2 clinical trials.
How does Insulin Zinc, Prompt work?
Insulin Zinc, Prompt works as an agonist of the insulin receptor. This means it binds to and activates the insulin receptor, thereby mimicking the effects of insulin in the body.
What is Insulin Zinc, Prompt studied for?
Insulin Zinc, Prompt has been mentioned in studies related to various conditions, including Maple Syrup Urine Disease, Diabetic Ketoacidosis, and Zinc Deficiency.
What is the regulatory status of Insulin Zinc, Prompt?
Insulin Zinc, Prompt is currently in Phase 2 clinical trials, indicating it is undergoing further evaluation for its potential therapeutic uses.

6 References

  1. Insulin Zinc, Prompt — molecule record ChEMBL. View source
  2. Insulin Zinc, Prompt — published literature (7 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Insulin Zinc, Prompt.

Insulin Glargineapproved

Also targets Insulin receptor

Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.

Insulin Aspartapproved

Also targets Insulin receptor

Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.

Insulin Lisproapproved

Also targets Insulin receptor

Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.

Insulin Degludecapproved

Also targets Insulin receptor

Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.

Insulin Detemirapproved

Also targets Insulin receptor

Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.

Insulin Zincapproved

Also targets Insulin receptor

Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.

7 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.